← All trials
NCT07310134
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2025
- Primary completion
- Nov 30, 2026
- Completion date
- Dec 30, 2026
- First posted
- Dec 30, 2025
- Last posted
- Dec 30, 2025
- Enrollment
- 80
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hangzhou Zenshine Pharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.